Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Century Therapeutics, Inc. (IPSC)
Company Research
Source: GlobeNewswire
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage aß iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and investments of $249.9 million; Cash runway into 2026 PHILADELPHIA, May 09, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today re
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingGlobeNewswire
- Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit [Yahoo! Finance]Yahoo! Finance
IPSC
Earnings
- 5/9/24 - Beat
IPSC
Analyst Actions
- 3/15/24 - Canaccord Genuity
IPSC
Sec Filings
- 5/22/24 - Form 424B3
- 5/22/24 - Form EFFECT
- 5/21/24 - Form 4
- IPSC's page on the SEC website